10d
Clinical Trials Arena on MSNGSK reports positive outcomes from two Phase III trials of treatment for CRSwNPSecondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.
which was related to a one-time voluntary retirement scheme (VRS). Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic ...
A pooled analysis of both trials showed notable reductions from baseline in nasal polyp score (NPS) at 52 weeks and mean nasal obstruction scores (VRS) for over weeks 49-52. GSK said that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results